Report Detail

Pharma & Healthcare Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2019

  • RnM3727943
  • |
  • 05 September, 2019
  • |
  • Global
  • |
  • 74 Pages
  • |
  • Global Markets Direct
  • |
  • Pharma & Healthcare

Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2019, provides an overview of the Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline landscape.

Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 8, 2, 3, 1 and 2 respectively.

Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Onychomycosis (Tinea Unguium) - Overview

              Onychomycosis (Tinea Unguium) - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Products under Development by Companies

                      Onychomycosis (Tinea Unguium) - Therapeutics Assessment

                        Assessment by Target

                          Assessment by Mechanism of Action

                            Assessment by Route of Administration

                              Assessment by Molecule Type

                                Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development

                                  Almirall SA

                                    Ascil Proyectos SL

                                      Blueberry Therapeutics Ltd

                                        Hexima Ltd

                                          Kaken Pharmaceutical Co Ltd

                                            Meiji Seika Pharma Co Ltd

                                              Moberg Pharma AB

                                                NAL Pharmaceuticals Ltd

                                                  Novabiotics Ltd

                                                    Novan Inc

                                                      Photonamic GmbH & Co KG

                                                        Onychomycosis (Tinea Unguium) - Drug Profiles

                                                          aminolevulinic acid hydrochloride - Drug Profile

                                                            Product Description

                                                              Mechanism Of Action

                                                                R&D Progress

                                                                  Amphotericin B sodium - Drug Profile

                                                                    Product Description

                                                                      Mechanism Of Action

                                                                        R&D Progress

                                                                          BB-0305 - Drug Profile

                                                                            Product Description

                                                                              Mechanism Of Action

                                                                                R&D Progress

                                                                                  DBI-001 - Drug Profile

                                                                                    Product Description

                                                                                      Mechanism Of Action

                                                                                        R&D Progress

                                                                                          ELS-160 - Drug Profile

                                                                                            Product Description

                                                                                              Mechanism Of Action

                                                                                                R&D Progress

                                                                                                  HXP-124 - Drug Profile

                                                                                                    Product Description

                                                                                                      Mechanism Of Action

                                                                                                        R&D Progress

                                                                                                          KP-607 - Drug Profile

                                                                                                            Product Description

                                                                                                              Mechanism Of Action

                                                                                                                R&D Progress

                                                                                                                  ME-1111 - Drug Profile

                                                                                                                    Product Description

                                                                                                                      Mechanism Of Action

                                                                                                                        R&D Progress

                                                                                                                          NAL-3210 - Drug Profile

                                                                                                                            Product Description

                                                                                                                              Mechanism Of Action

                                                                                                                                R&D Progress

                                                                                                                                  NORS-0791 - Drug Profile

                                                                                                                                    Product Description

                                                                                                                                      Mechanism Of Action

                                                                                                                                        R&D Progress

                                                                                                                                          NP-213 - Drug Profile

                                                                                                                                            Product Description

                                                                                                                                              Mechanism Of Action

                                                                                                                                                R&D Progress

                                                                                                                                                  onymed - Drug Profile

                                                                                                                                                    Product Description

                                                                                                                                                      Mechanism Of Action

                                                                                                                                                        R&D Progress

                                                                                                                                                          oteseconazole - Drug Profile

                                                                                                                                                            Product Description

                                                                                                                                                              Mechanism Of Action

                                                                                                                                                                R&D Progress

                                                                                                                                                                  P-3058 - Drug Profile

                                                                                                                                                                    Product Description

                                                                                                                                                                      Mechanism Of Action

                                                                                                                                                                        R&D Progress

                                                                                                                                                                          SB-208 - Drug Profile

                                                                                                                                                                            Product Description

                                                                                                                                                                              Mechanism Of Action

                                                                                                                                                                                R&D Progress

                                                                                                                                                                                  terbinafine hydrochloride - Drug Profile

                                                                                                                                                                                    Product Description

                                                                                                                                                                                      Mechanism Of Action

                                                                                                                                                                                        R&D Progress

                                                                                                                                                                                          terbinafine hydrochloride - Drug Profile

                                                                                                                                                                                            Product Description

                                                                                                                                                                                              Mechanism Of Action

                                                                                                                                                                                                R&D Progress

                                                                                                                                                                                                  terbinafine hydrochloride - Drug Profile

                                                                                                                                                                                                    Product Description

                                                                                                                                                                                                      Mechanism Of Action

                                                                                                                                                                                                        R&D Progress

                                                                                                                                                                                                          Onychomycosis (Tinea Unguium) - Dormant Projects

                                                                                                                                                                                                            Onychomycosis (Tinea Unguium) - Discontinued Products

                                                                                                                                                                                                              Onychomycosis (Tinea Unguium) - Product Development Milestones

                                                                                                                                                                                                                Featured News & Press Releases

                                                                                                                                                                                                                  Mar 22, 2019: Moberg Pharma completes enrollment for MOB-015 phase 3 study in Europe

                                                                                                                                                                                                                    Dec 18, 2018: Almirall announces that the Phase III trial of P-3058 for onychomycosis achieved primary endpoint

                                                                                                                                                                                                                      Nov 23, 2018: Moberg Pharma: Patent granted for MOB-015 in China

                                                                                                                                                                                                                        Sep 11, 2018: Moberg Pharma has completed enrollment to Phase 3 study for MOB-015 in North America

                                                                                                                                                                                                                          May 17, 2018: SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment

                                                                                                                                                                                                                            Jan 11, 2018: Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference

                                                                                                                                                                                                                              Nov 20, 2017: Moberg Pharma replaces CRO in Phase 3 studies for MOB-015

                                                                                                                                                                                                                                Nov 08, 2017: Moberg Pharma provides update on timeline for MOB-015

                                                                                                                                                                                                                                  Jul 27, 2017: Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the American Podiatric Medical Association Annual Meeting

                                                                                                                                                                                                                                    Jun 21, 2017: Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the 4th International Summit on Nail Diseases

                                                                                                                                                                                                                                      Apr 12, 2017: Novan Reports Positive Topline Results with SB208 in Phase 2 Trial

                                                                                                                                                                                                                                        Mar 06, 2017: Viamet Presents Positive Results from Phase 2b Trial of VT-1161 in Onychomycosis at the American Academy of Dermatology Annual Meeting

                                                                                                                                                                                                                                          Mar 01, 2017: Viamet Announces RENOVATE Phase 2b Onychomycosis Results to be Presented at the American Academy of Dermatology 2017 Annual Meeting

                                                                                                                                                                                                                                            Nov 08, 2016: Hallux Announces Start of Phase 2 Clinical Trial

                                                                                                                                                                                                                                              Sep 28, 2016: Moberg Pharma Begins Patient Enrollment in North America and Europe in Two Phase 3 Studies of MOB-015 in Onychomycosis

                                                                                                                                                                                                                                                Appendix

                                                                                                                                                                                                                                                  Methodology

                                                                                                                                                                                                                                                    Coverage

                                                                                                                                                                                                                                                      Secondary Research

                                                                                                                                                                                                                                                        Primary Research

                                                                                                                                                                                                                                                          Expert Panel Validation

                                                                                                                                                                                                                                                            Contact Us

                                                                                                                                                                                                                                                              Disclaimer

                                                                                                                                                                                                                                                              Summary:
                                                                                                                                                                                                                                                              Get latest Market Research Reports on Onychomycosis (Tinea Unguium). Industry analysis & Market Report on Onychomycosis (Tinea Unguium) is a syndicated market report, published as Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2019. It is complete Research Study and Industry Analysis of Onychomycosis (Tinea Unguium) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                                                                                                                                                              Last updated on

                                                                                                                                                                                                                                                              REPORT YOU MIGHT BE INTERESTED

                                                                                                                                                                                                                                                              Purchase this Report

                                                                                                                                                                                                                                                              $2,000.00
                                                                                                                                                                                                                                                              $4,000.00
                                                                                                                                                                                                                                                              $6,000.00
                                                                                                                                                                                                                                                              1,584.00
                                                                                                                                                                                                                                                              3,168.00
                                                                                                                                                                                                                                                              4,752.00
                                                                                                                                                                                                                                                              1,848.00
                                                                                                                                                                                                                                                              3,696.00
                                                                                                                                                                                                                                                              5,544.00
                                                                                                                                                                                                                                                              302,580.00
                                                                                                                                                                                                                                                              605,160.00
                                                                                                                                                                                                                                                              907,740.00
                                                                                                                                                                                                                                                              166,740.00
                                                                                                                                                                                                                                                              333,480.00
                                                                                                                                                                                                                                                              500,220.00
                                                                                                                                                                                                                                                              Credit card Logo

                                                                                                                                                                                                                                                              Related Reports


                                                                                                                                                                                                                                                              Reason to Buy

                                                                                                                                                                                                                                                              Request for Sample of this report